AOD-9604 and Retatrutide Together: What Is Known
AOD-9604 and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | AOD-9604 | Retatrutide |
|---|---|---|
| Class | HGH fragment analog | GLP-1 / GIP / glucagon triple agonist |
| Also called | AOD | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
AOD-9604 vs Retatrutide
Choosing between the two rather than combining them? The comparison lines them up field by field.
Retatrutide has randomized human weight data
In the phase 2 obesity trial, 24-week body weight change was -7.2% in the 1 mg group, -12.9% in the combined 4 mg group, -17.3% in the combined 8 mg group and -17.5% in the 12 mg group, against -1.6% on placebo.[15]
In the phase 3 trial, mean body weight change was -25.0% on 12 mg against -3.9% on placebo.[1]
AOD-9604 does not
AOD9604 weight work was done in rats: 19 days of oral dosing reduced weight gain by over half.[8]
The mouse studies added that AOD-linked weight loss was tied to higher fat oxidation.[16]
Reported adverse events
In the phase 3 obesity trial, the most common adverse events with retatrutide were gastrointestinal.[1]
Together
The search for AOD-9604 with retatrutide returned 0 PubMed records.
Calculated from pubmed query ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key aod-9604__retatrutide); no arithmetic applied.
Retatrutide has no approved product: Drugs@FDA returned no match.[17]
Common questions
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
- 7Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
- 8Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 9PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 11Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 12Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 16Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
- 17Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.